Marshall Wace LLP Buys New Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Marshall Wace LLP bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 67,684 shares of the company's stock, valued at approximately $665,000. Marshall Wace LLP owned 0.12% of Ginkgo Bioworks as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Erste Asset Management GmbH increased its position in Ginkgo Bioworks by 47.9% in the fourth quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after buying an additional 239,332 shares during the last quarter. Forbes J M & Co. LLP raised its stake in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock valued at $6,891,000 after acquiring an additional 576,732 shares during the period. Geode Capital Management LLC increased its stake in shares of Ginkgo Bioworks by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock worth $4,294,000 after purchasing an additional 20,394 shares in the last quarter. Monaco Asset Management SAM raised its position in shares of Ginkgo Bioworks by 3.9% in the fourth quarter. Monaco Asset Management SAM now owns 384,664 shares of the company's stock valued at $3,777,000 after purchasing an additional 14,539 shares during the period. Finally, Prescott Group Capital Management L.L.C. lifted its stake in shares of Ginkgo Bioworks by 33.1% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company's stock valued at $3,552,000 after buying an additional 90,000 shares in the last quarter. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock traded up $0.95 during mid-day trading on Wednesday, reaching $7.40. The company's stock had a trading volume of 1,787,585 shares, compared to its average volume of 1,479,335. The company has a market capitalization of $429.16 million, a P/E ratio of -0.57 and a beta of 1.29. The firm's fifty day moving average price is $7.14 and its two-hundred day moving average price is $9.09. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $38.58.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The company had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.